| Literature DB >> 24836761 |
Christen Lykkegaard Andersen1, Mads Emil Bjørn2, Mary Frances McMullin3, Claire Harrison4, Jan Samuelsson5, Elisabeth Ejerblad6, Sonja Zweegman7, Savio Fernandes8, David Bareford8, Steven Knapper9, Eva Löfvenberg10, Olle Linder11, Bjørn Andreasson12, Erik Ahlstrand11, Morten Krogh Jensen13, Ole Weis Bjerrum14, Hanne Vestergaard15, Herdis Larsen16, Tobias Wirenfeldt Klausen13, Torben Mourits-Andersen17, Vibe Skov18, Mads Thomassen18, Torben Kruse18, Kirsten Grønbæk14, Hans Carl Hasselbalch2.
Abstract
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.Entities:
Keywords: Essential thrombocythemia; Phase II study; Polycythemia vera; Vorinostat; Ykl-40
Mesh：
Substances：
Year: 2014 PMID： 24836761 DOI： 10.1016/j.leukres.2014.04.002
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156